dc.contributor.author | Muganzi, Alex Muganga | |
dc.date.accessioned | 2013-01-16T11:25:55Z | |
dc.date.available | 2013-01-16T11:25:55Z | |
dc.date.issued | 2009-10 | |
dc.identifier.uri | http://hdl.handle.net/10570/1009 | |
dc.description | A dissertation submitted in partial fulfillment of the requirements for the award of the Degree of Master of Public Health of Makerere University | en_US |
dc.description.abstract | BACKGROUND:
In Africa, a consideration number of clients get diagnosed with HIV for the first time after a WHO stage 4 illness. Evidence in the developed world shows that individuals who initiate ART with advanced HIV/AIDS may not have as good responses as those with early HIV disease. Data on this important subject in Africa is limited.
OBJECTIVE:
Compare clinical and immunological treatment outcomes in individuals with WHO stage 4 versus stage 2 and 3 disease.
METHODS:
496 adults HIV infected ART naïve patients were evaluated. Clinical and immunological parameters were analysed at baseline, six and 12 months of HAART.
RESULTS:
HARRT initiation resulted in rise in absolute CD4 counts and improvement of clinical parameters. Responses were better for WHO stage 2 and 3 than stage 4. After 6 months of HAART initiation, there was a statistically significant difference in the livelihood of being diagnosed with OLs between the two groups (RR=0.09, 95%C1=0.012-0.690). At 6 months after HAART initiation, the difference in the mean karnofsky score between the two categories of patients was statistically significant with a mean difference of 3% (95% C1=0.476, 3.62). At 12 months, the difference in the mean karnofsky score between the two categories of patients was statistically significant with a mean difference of 4.0% (95% C1=0.602 to 5.00)
CONCLUSION:
Better clinical and immunological treatment responses were noted in WHO stage 2 and 3 compared to stage 4 and at 12 months of HAART compared to 6 months. Individuals initiating ART with advanced disease in Africa do not show good clinical and immunological responses compared to those with early symptomatic disease. | en_US |
dc.language.iso | en | en_US |
dc.subject | HAART | en_US |
dc.subject | HIV/AIDS | en_US |
dc.subject | Antiretroviral therapy | en_US |
dc.subject | ART | en_US |
dc.subject | Infectious Diseases Institute | en_US |
dc.subject | Africa | en_US |
dc.title | Evaluation of patients' response to treatment with highly active antiretroviral therapy at the Infectious Diseases Institute, Kampala. | en_US |
dc.type | Thesis, masters | en_US |